Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Front Immunol. 2020 Feb 7;10:3084. doi: 10.3389/fimmu.2019.03084. eCollection 2019.
Kaposi's sarcoma (KS)-associated herpesvirus (KSHV) is associated with KS, primary effusion lymphoma (PEL), and multicentric Castleman disease (MCD). To ensure its own survival and propagation, KSHV employs an extensive network of viral proteins to subvert the host immune system, resulting in lifelong latent infection. Modulation of cellular and systemic immune defenses allows KSHV to persist in the host, which may eventually lead to the progression of KSHV-associated cancers. Due to KSHV's reliance on modifying immune responses to efficiently infect its host, immunotherapy is an attractive option for treating KSHV-associated malignancies. In this review, we will focus on the mechanisms by which KSHV evades the immune system and the current immune-related clinical strategies to treat KSHV-associated disease.
卡波西肉瘤相关疱疹病毒（KSHV）与卡波西肉瘤、原发性渗出性淋巴瘤（PEL）和多中心 Castleman 病（MCD）有关。为了确保自身的生存和繁殖，KSHV 利用大量的病毒蛋白来颠覆宿主的免疫系统，导致终身潜伏感染。细胞和全身免疫防御的调节使 KSHV 在宿主体内存活，这可能最终导致 KSHV 相关癌症的进展。由于 KSHV 依赖于改变免疫反应来有效地感染其宿主，免疫疗法是治疗 KSHV 相关恶性肿瘤的一种有吸引力的选择。在这篇综述中，我们将重点讨论 KSHV 逃避免疫系统的机制，以及目前用于治疗 KSHV 相关疾病的免疫相关临床策略。
